Article Text

Download PDFPDF
Antibodies to GM1: galactocerebroside complexes in multifocal motor neuropathy: it takes two to tango
  1. Hugh J Willison,
  2. Francesc Galban-Horcajo,
  3. Susan K Halstead
  1. Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
  1. Correspondence to Professor Hugh J Willison, Glasgow Biomedical Research Centre, Room B330, 120 University Place, University of Glasgow, Glasgow G12 8TA, UK; Hugh.Willison{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In the mid-1980s, Pestronk reported the first cases of multifocal motor neuropathy to be associated with serum anti-monosialoganglioside (GM1) IgM antibodies.1 The potential importance of an easily measurable antibody as a biomarker for this diagnostically challenging but treatable neurological disorder was rapidly recognised. Subsequently, an extensive literature has emerged on the usefulness of anti-GM1 antibody testing in clinical practice and on its relationship to multifocal motor neuropathy (MMN) pathogenesis. The conventional ELISA sensitivity is currently considered to be around 50%; perhaps as a result of this rather poor performance, many clinicians pay scant notice to a positive or negative result, preferring to use clinical judgment and electrophysiological assessment as the …

View Full Text


  • Contributors WHJ, G-HF and HSK equally contributed to this article.

  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles